What adverse reactions happened during this study?
The most common adverse reaction was weakness. The table below shows the
adverse reactions that happened in 5.0% or more of participants during the study.
There were other adverse reactions, but these happened in fewer participants.
Most common adverse reactions
Adverse reaction Out of 867 participants
Weakness 9.9% (86)
Itching 9.0% (78)
Diarrhea 7.0% (61)
An underactive thyroid gland 5.3% (46)
How has this study helped patients and
researchers?
This study helped researchers learn more about the safety of durvalumab in
participants with cancer of the urinary tract that has spread outside the urinary
tract.
Researchers look at the results of many studies to decide which treatments work
best and are safest. This summary shows only the main results from this one study.
Other studies may provide new information or different results.
Further clinical studies with durvalumab are ongoing.
11 | Clinical Study Results